特应性皮炎的治疗管理。

IF 0.6 Q4 NURSING
NURSE PRACTITIONER Pub Date : 2024-06-01 Epub Date: 2024-05-23 DOI:10.1097/01.NPR.0000000000000183
Lynda Jarrell
{"title":"特应性皮炎的治疗管理。","authors":"Lynda Jarrell","doi":"10.1097/01.NPR.0000000000000183","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Atopic dermatitis (AD), a chronic inflammatory, pruritic skin disorder, is seen primarily in the pediatric population but can be found among all age groups. The symptoms of AD can cause embarrassment in patients and can interrupt daily activities and productivity, potentially resulting in avoidance of social situations. In addition to nonpharmacologic management, mainstay pharmacologic treatments for AD are topical medications including corticosteroids, calcineurin inhibitors, phosphodiesterase-4 inhibitors, and topical Janus kinase (JAK) inhibitors. Promising new drugs-oral JAK inhibitors and monoclonal antibodies-have emerged as new treatment options for moderate-to-severe AD.</p>","PeriodicalId":51812,"journal":{"name":"NURSE PRACTITIONER","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Therapeutic management of atopic dermatitis.\",\"authors\":\"Lynda Jarrell\",\"doi\":\"10.1097/01.NPR.0000000000000183\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>Atopic dermatitis (AD), a chronic inflammatory, pruritic skin disorder, is seen primarily in the pediatric population but can be found among all age groups. The symptoms of AD can cause embarrassment in patients and can interrupt daily activities and productivity, potentially resulting in avoidance of social situations. In addition to nonpharmacologic management, mainstay pharmacologic treatments for AD are topical medications including corticosteroids, calcineurin inhibitors, phosphodiesterase-4 inhibitors, and topical Janus kinase (JAK) inhibitors. Promising new drugs-oral JAK inhibitors and monoclonal antibodies-have emerged as new treatment options for moderate-to-severe AD.</p>\",\"PeriodicalId\":51812,\"journal\":{\"name\":\"NURSE PRACTITIONER\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NURSE PRACTITIONER\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.NPR.0000000000000183\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"NURSING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NURSE PRACTITIONER","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.NPR.0000000000000183","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0

摘要

摘要:特应性皮炎(AD)是一种慢性炎症性、瘙痒性皮肤病,主要见于儿童群体,但也可见于所有年龄组。特应性皮炎的症状会使患者感到尴尬,影响日常活动和工作效率,并可能导致患者回避社交场合。除了非药物治疗外,AD 的主要药物治疗方法是局部用药,包括皮质类固醇激素、钙神经蛋白抑制剂、磷酸二酯酶-4 抑制剂和局部 Janus 激酶(JAK)抑制剂。口服JAK抑制剂和单克隆抗体是治疗中度至重度AD的新药,前景看好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Therapeutic management of atopic dermatitis.

Abstract: Atopic dermatitis (AD), a chronic inflammatory, pruritic skin disorder, is seen primarily in the pediatric population but can be found among all age groups. The symptoms of AD can cause embarrassment in patients and can interrupt daily activities and productivity, potentially resulting in avoidance of social situations. In addition to nonpharmacologic management, mainstay pharmacologic treatments for AD are topical medications including corticosteroids, calcineurin inhibitors, phosphodiesterase-4 inhibitors, and topical Janus kinase (JAK) inhibitors. Promising new drugs-oral JAK inhibitors and monoclonal antibodies-have emerged as new treatment options for moderate-to-severe AD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.90
自引率
0.00%
发文量
183
期刊介绍: With a circulation of 20,000, The Nurse Practitioner is the leading monthly source for clinical, practical, cutting-edge information for advanced practice nurses and other primary care clinicians. Each issue presents peer-reviewed articles that range from clinical topics and research to political and practice issues. In addition, The Nurse Practitioner provides regular features, columns, continuing education, staff development education, and more.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信